双歧杆菌三联活菌片联合艾司奥美拉唑治疗胃溃疡的研究

Objective On the effectiveness of combining bifidobacterium triple viable powder with esomeprazole for gastric ulcer therapy. Methods 80 cases of gastric ulcer patients admitted to Zhashui County People's Hospital from August 2023 to August 2024 were selected and grouped by randomized numerical table method, 40 cases each in the control group and the combined group. The patients in the control group were given esomeprazole magnesium enteric-coated tablets in addition to two kinds of antibiotics treatment, while the patients in the combined group were given bifidobacterium bifidum triple tablets in addition to the control group's treatment. Both groups were treated continuously for 21 days. The clinical efficacy, incidence of adverse reactions, gastric mucosa indicators, and inflammatory indicators before and after treatment were compared between the two groups. Results After 21 days of treatment, the clinical efficacy of the combined group was higher than that of the control group(P<0.05). The levels of vascular endothelial growth factor(VEGF), epidermal growth factor(EGF), and cyclooxygenase-2(COX-2) in the combined group were all higher than those in the control group(P<0.05). The levels of inflammatory indicators such as tumor necrosis factor-α(TNF-α), interleukin-6(IL-6), and C-reactive protein(CRP) in the combined group were all lower than those in the control group(P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion The combination of bifidobacterium bifidum triple tablets and esomeprazole has a remarkable clinical effect in treating gastric ulcers. It can effectively promote the recovery of the gastric mucosa, reduce inflammatory reactions, and has good safety.